An oral JAK1/TYK2 inhibitor reported high phase 2 EASI-75 rates in atopic dermatitis

Design

Phase 2, randomised, double-blind, placebo-controlled dose-finding trial

Population

200 adults in China with moderate-to-severe atopic dermatitis

Primary outcome

EASI-75 at week 12

Effect

72.9%, 84.7% and 81.4% (5, 10, 20 mg BID) vs 18.5% placebo

QY201 is an investigational oral inhibitor of JAK1 and TYK2. This phase 2 dose-finding trial in China randomised 200 adults with moderate-to-severe atopic dermatitis to 5, 10 or 20 mg twice daily or placebo for 12 weeks.

EASI-75 at week 12 was reached by 72.9%, 84.7% and 81.4% across the three doses against 18.5% with placebo. IGA response was 44.7%, 64.3% and 71.3% against 12.4%. Adverse events occurred in 74.0%, 75.5% and 90.4% on QY201 and 69.4% on placebo, mostly mild or moderate.

Twelve weeks in one country is too short and too narrow to judge the safety questions that follow every JAK inhibitor. The drug is not approved anywhere.

This is a pipeline result to note, not a prescribing option.

• EASI-75 at 12 weeks was 73-85% across doses against 18.5% with placebo.
• Adverse events were most frequent at the 20 mg dose.
• The trial lasted 12 weeks in a single country.
• QY201 is investigational and not approved by any regulator.
• Long-term JAK-class safety questions remain untested for this drug.

Why it matters

The oral JAK option in atopic dermatitis may widen, with dosing likely to be set at 10 or 20 mg twice daily.

Don't overread it

This is phase 2 evidence over 12 weeks; it says nothing about long-term safety.

The statistics, in plain English

The gap from placebo is large and very unlikely to be chance. But phase 2 trials are small and short, and effect sizes often shrink in phase 3.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.